Source:http://linkedlifedata.com/resource/pubmed/id/12629773
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2003-3-12
|
pubmed:abstractText |
We examined the usefulness of prostate specific antigen alph-1-antichymotrypsin complex (PSA-ACT) and its indices for the detection of prostate cancer in patients with a prostate specific antigen (PSA) level between 2.1 and 10.0 ng/ml. Between July 1999 and October 2001, 151 patients with a PSA level between 2.1 and 10.0 ng/ml underwent a systematic biopsy under transrectal ultrasound (TRUS) guidance. The clinical values of total PSA, PSA-ACT, PSA density (PSAD), PSA-ACT density (PSA-ACTD), PSA transition zone density (PSATZD) and PSA-ACT transition zone density (PSA-ACTTZD) for the detection of prostate cancer were compared by using receiver operating characteristic (ROC) curve analysis. Of the 151 patients, 36 (23.8%) were histologically confirmed as having prostate cancer. The differences between patients with prostate cancer and benign prostatic disease were significant with respect to the PSA and PSA-ACT related parameters examined in this study. According to ROC curve analysis, the area under the curve (AUC) of PSA-ACTTZD was the greatest of all the parameters. The differences was significant between the AUC of PSA-ACTTZD and total PSA (p < 0.05). The cutoff value of PSA-ACTTZD with 0.20 ng/ml2 showed the highest sum of sensivitity (90%) and specificity (55%). Also, in 86 patients with a PSA level between 2.1 and 6.0 ng/ml, the AUC of PSA-ACTTZD was the greatest of all the parameters. Measuring the level of PSA-ACT and its indices may provide a better differentiation of prostate cancer and benign prostatic disease than total PSA alone in patients with intermediate PSA levels. PSA-ACTTZD is the most useful indicator among PSA-ACT and its volume indices.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0018-1994
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
49
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5-10
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12629773-Aged,
pubmed-meshheading:12629773-Aged, 80 and over,
pubmed-meshheading:12629773-Area Under Curve,
pubmed-meshheading:12629773-Diagnosis, Differential,
pubmed-meshheading:12629773-Humans,
pubmed-meshheading:12629773-Male,
pubmed-meshheading:12629773-Middle Aged,
pubmed-meshheading:12629773-Prostate-Specific Antigen,
pubmed-meshheading:12629773-Prostatic Neoplasms,
pubmed-meshheading:12629773-ROC Curve,
pubmed-meshheading:12629773-Sensitivity and Specificity,
pubmed-meshheading:12629773-Tumor Markers, Biological,
pubmed-meshheading:12629773-alpha 1-Antichymotrypsin
|
pubmed:year |
2003
|
pubmed:articleTitle |
The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
|
pubmed:affiliation |
Department of Urology, Hyogo Prefectural Awaji Hospital.
|
pubmed:publicationType |
Journal Article
|